Ursprung des Netzwerks ersten Grades von Tsutomu Mori
| Einheit | Art der Einheit | Industrie | |
|---|---|---|---|
Biocomm Square Pty Ltd.
 Biocomm Square Pty Ltd. Miscellaneous Commercial ServicesCommercial Services Biocomm Square Pty Ltd. provides business development and licensing consulting services. The firm provides business development and licensing, corporate strategy, business planning, project management and portfolio review and technology assessment services. It also offers services like market analysis, competitive intelligence, scientific and commercial evaluation and assessment, in and out licensing strategy development, arrangement and implementation, research collaboration and alliances, biotechnology, biopharmaceuticals and cellular therapeutics services. The company was founded by Andrew John Hubert Gearing and Tsutomu Mori in 2007 and is headquartered in Clayton, Australia.
2
| Private Company | Miscellaneous Commercial Services | 2 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von Tsutomu Mori
| Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
|---|---|---|---|
Genesis Research & Development Corp. Ltd.
 Genesis Research & Development Corp. Ltd. Financial ConglomeratesFinance Genesis Research & Development Corp. Ltd. operates as a development stage company. Previously, it was a technology investment company that builds a broad therapeutic development platform targeting immune disorders and cancer and a novel single stranded gene silencing technology using the RNAi mechanism. The company was founded by James Douglas Watson in 1994 and is headquartered in Auckland, New Zealand. | Financial Conglomerates | Director/Board Member | |
| BioMelbourne Network | Director/Board Member | ||
Nexvet Australia Pty Ltd.
 Nexvet Australia Pty Ltd. Pharmaceuticals: MajorHealth Technology Nexvet Australia Pty Ltd. operates as a global clinical-stage biopharmaceutical company that develops and distributes medicines for companion animals. The firm focuses on transforming the therapeutic market by developing and commercializing novel biologic therapies, including products derived from its PETization technology. PETization is designed to rapidly create monoclonal antibodies that are recognized as “self” by a patient’s immune system. The company was founded by Mark Heffernan, Christopher Nigel Brown and David Gearing in February 2010 and is headquartered in Melbourne, Australia. | Pharmaceuticals: Major | Director/Board Member | |
| National Institute of Biological Standards & Control | Corporate Officer/Principal |
Statistik
International
| Australien | 5 |
| Neuseeland | 2 |
| Vereinigte Staaten | 2 |
Sektoral
| Health Technology | 4 |
| Finance | 2 |
Operativ
| Director/Board Member | 4 |
| Chief Executive Officer | 2 |
| Founder | 2 |
| Corporate Officer/Principal | 2 |
| Independent Dir/Board Member | 1 |
Am stärksten vernetzte Beziehungen
- Börse
- Insiders
- Tsutomu Mori
- Unternehmensverbindungen
